TABLE 4.
Emax and EC50 values and respective 95% confidence intervals derived by fitting the inhibitory sigmoid Emax equation to all of the dose-response data for the three Staphylococcus aureus isolates for six of the parenteral vancomycin products available in the United States
| Bacterial isolate | Vancomycin product | Emaxa (95% CIc) | EC50b (95% CI) | r2d |
|---|---|---|---|---|
| GRP-0057 | A | 4.425 (2.822 to 6.027) | 37.31 (17.89 to 56.72) | 0.947 |
| B | 4.977 (4.232 to 5.721) | 50.70 (36.96 to 64.44) | 0.999 | |
| C | 5.217 (4.917 to 5.517) | 39.75 (32.97 to 46.52) | 0.995 | |
| D | 4.892 (4.611 to 5.172) | 45.15 (38.96 to 51.33) | 0.999 | |
| E | 4.920 (4.530 to 5.311) | 38.29 (36.63 to 39.96) | 0.975 | |
| F | 4.985 (4.698 to 5.271) | 43.43 (25.50 to 61.35) | 0.989 | |
| ATCC 33591 | A | 4.981 (4.754 to 5.209) | 22.33 (14.17 to 30.50) | 0.985 |
| B | 5.349 (3.720 to 6.979) | 24.88 (−5.339 to 55.10) | 0.966 | |
| C | 5.372 (3.670 to 7.073) | 18.97 (−3.333 to 41.26) | 0.847 | |
| D | 5.093 (4.001 to 6.185) | 17.50 (10.80 to 24.20) | 0.989 | |
| E | 5.440 (5.145 to 5.736) | 22.59 (15.85 to 29.34) | 0.985 | |
| F | 4.934 (4.460 to 5.409) | 18.34 (14.74 to 21.93) | 0.950 | |
| ATCC 29213 | A | 5.675 (5.318 to 6.032) | 17.10 (13.43 to 20.77) | 0.922 |
| B | 5.728 (5.250 to 6.206) | 14.87 (8.064 to 21.67) | 0.961 | |
| C | 5.369 (4.852 to 5.886) | 18.21 (15.20 to 21.22) | 0.621 | |
| D | 5.893 (5.462 to 6.324) | 27.35 (10.59 to 44.10) | 0.996 | |
| E | 6.078 (4.650 to 7.507) | 29.37 (4.692 to 54.05) | 0.861 | |
| F | 5.898 (5.284 to 6.511) | 29.47 (12.92 to 46.02) | 0.967 |
a
Emax is the maximal cell kill generated by the product.
b
EC50 is the vancomycin product dose that produces half the maximal cell kill.
c
CI, confidence interval.
d
r2 value for inhibitory sigmoid Emax relationship.